Generic Name and Formulations:
Acitretin 10mg, 17.5mg, 25mg; caps.
Stiefel Laboratories, Inc.
Indications for SORIATANE:
Severe psoriasis (in female patients of reproductive potential, use only if unresponsive to or cannot take other agents).
25–50mg once daily with main meal; may discontinue when lesions resolve. May repeat if relapse occurs. Prescribe limited supply. Decrease phototherapy dose.
Alcohol. Concomitant methotrexate, tetracyclines. Severe hepatic or renal impairment. Dyslipidemias. Pregnancy (Cat.X). Retinoid hypersensitivity.
Be fully familiar with toxicity and teratogenicity before use. Transient worsening of symptoms may occur. Females of reproductive potential (including history of infertility): obtain 2 reliable (–) pregnancy tests (when decision is made to start and during first 5 days of menstrual period prior to treatment initiation) and repeat periodically (eg, monthly); use at least 2 reliable methods of contraception or abstain for at least 1 month before, during, and for 3 years after therapy (if etretinate had been used previously, continue to follow contraception recommendations for that product). Discontinue if hepatotoxicity is suspected, if papilledema (refer to neurologist), visual difficulties (refer to ophthalmologist), psychiatric symptoms (eg, depression), capillary leak syndrome, or exfoliative dermatitis/erythroderma occurs. Monitor for ossification abnormalities. Do pretreatment blood lipid evaluation and repeat at 1–2 week intervals until lipid response established; control significant triglyceride elevations with diet, drugs, or dose reduction; consider discontinuing if hypertriglyceridemia and low HDL levels persist. Perform LFTs prior to initiation, at 1–2 week intervals until stable, and thereafter as clinically indicated. Avoid sun and UV light. Monitor diabetics. Do not donate blood during and for 3 years after therapy. Get written informed consent. Elderly. Nursing mothers: not recommended.
See Contraindications (methotrexate increases risk of hepatitis; tetracycline increases intracranial pressure). Females must not ingest ethanol during or for 2 months after therapy (prolongs teratogenic potential). Microdosed "minipill" progestin preparations: not recommended. May interfere with other progestin-only contraceptives (eg, injectables, implants). Avoid St. John's wort, others that may decrease efficacy of contraceptives, vitamin A, other oral retinoids. May potentiate phenytoin, sulfonylureas.
Lipid elevations, abnormal LFTs and other lab tests, cardiovascular effects, psychiatric symptoms, chelitis, alopecia, skin peeling, dry or sticky skin, nail disorder, pruritus, dry mouth, rhinitis, hypervitaminosis A syndrome, epistaxis, rash, hyperesthesia, paresthesia, xerophthalmia, dry or irritated eye, loss of eye brow or lashes, decreased night vision, intolerance to contact lenses, arthralgia, spinal hyperostosis, rigors; rare: pseudotumor cerebri, pancreatitis, hepatitis.
Call (888) 784-3335 or visit www.soriatane.com for information on the Do Your P.A.R.T. program.
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder